CTRI/2023/05/053344尚未招募1 期
Effect of Survali as an adjuvant in Type-2 Diabetes Mellitus: A randomized Placebo Controlled study
ational Institute of Unani Medicine0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Known cases of Type 2 Diabetes mellitus, on <= 2 hypoglycemic drugs
- •2.Fasting blood sugar (FBS) >= 126 mg/dl <= 200 mg/dl
- •3.Postprandial blood sugar (PPBS) >= 140 mg/dl <= 250mg /dl
- •4.HbA1c >= 6.5% to 8.5%
- •5.Both genders
- •6.Aged 30â??60 years
排除标准
- •1.Known cases of Type 2 Diabetes Mellitus on insulin or >=2 hypoglycemic drug with
- •complications
- •2.aged >60 years
- •3.Pregnant & lactating Women
- •4.History of systemic illnesses
- •5.History of other disorders of metabolism
研究者
相似试验
已完成
不适用
Sulfonylurea therapy added on type 2 diabetes patients with poorly controlled insulin therapy in Juntendotype 2 diabetesJPRN-UMIN000006765Juntendo University Graduate Schoolof Medicine.90
尚未招募
Unknown
A study to assess the effect of a combination of glucose lowering medicines in prevention of type 2 diabetes among women with previous history of gestational diabetes mellitus and having pre-diabetesCTRI/2024/05/067588Indian Council of Medical Research (ICMR)
尚未招募
不适用
A Comparison of Peri-Operative and Post Acute Coronary Syndrome Glycaemic Control in Insulin Requiring Patients with Type 2 Diabetes at St Vincent’s Hospital With and Without Real-Time Continuous Glucose Monitoring.Type 2 diabetes requiring insulinAcute coronary syndromesPost - operative patientsMetabolic and Endocrine - DiabetesCardiovascular - Coronary heart diseaseSurgery - Surgical techniquesACTRN12608000125325St Vincent's Hospital60
招募中
不适用
Effect of Novel Antidiabetic Drug Combined With Angiotensin Receptor/Neprilysin Inhibitor on Urinary ProteinType 2 DiabetesAntidiabetic DrugsNCT05922852Peking University Third Hospital1,000
已完成
3 期
Double blind, randomised, comparative, multicentre, parallel-group study design to evaluate the effects of Pioglitazone on cardiovascular risk markers in type 2 diabetes mellitusACTRN12608000534381Takeda Italia Farmaceutici S.p.A.100